By Jonathan Stempel NEW YORK (Reuters) -Bristol Myers Squibb won the dismissal of a proposed class action accusing it of ...

High-yielding dividend stocks can be great investments to hold on to in your portfolio, but only if they're safe. Betting on ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Sell rating on Bristol-Myers Squibb (BMY – Research Report), with a ...

Bristol-Myers Squibb (NYSE:BMY) recently announced positive topline results from its Phase 3 trials for Sotyktu, generating ...

Bristol-Myers Squibb (NYSE:BMY – Get Free Report) was the target of a significant growth in short interest during the month ...

Bristol-Myers Squibb awarded its CEO nearly $19 million in compensation for 2024, following a challenging year for the ...

Better-than-expected financial results in recent quarters have signaled an improved outlook, helping to sustain the rally.

Morgan Stanley lowered the firm’s price target on Bristol Myers (BMY) to $36 from $37 and keeps an Underweight rating on the shares. The firm ...

Learn more about whether Bristol-Myers Squibb Company or Jazz Pharmaceuticals plc is a better investment based on AAII's A+ ...

Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil Corporation (XOM), ...

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology ...

Walmart stock rises even as the retailer says the range of outcomes for first-quarter operating income growth had widened ...